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Abstract Tregitopes are regulatory T cell epitopes derived
from immunoglobulin G (IgG) that stimulate CD25+
FoxP3+ T cells to expand. In conjunction with these Tregs,
Tregitopes can prevent, treat, and even cure autoimmune
disease in mouse models, suppress allo-specific responses in
murine transplant models, inhibit CD8+ T cell responses to
recombinant adeno-associated virus (AAV) gene transfer
vectors, and induce adaptive Tregs in DO11.10 mice. In this
review of recent Tregitope studies, we summarize their
effects in vitro and describe recent comparisons between
intravenous IgG (IVIG) and Tregitopes in standard in vivo
immune tolerance models. Further investigations of the
mechanism of action of Tregitopes in the preclinical
models described here will lead to clinical trials where
Tregitopes may have the potential to alter the treatment
of autoimmune disease, transplantation, and allergy, and
to improve the efficiency of gene and protein replace-
ment therapies.
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Introduction to Tregitopes
In 2008 we discovered highly conserved, promiscuous T cell
epitopes in immunoglobulin G (IgG) [1]. As these epitopes
were highly conserved in the constant region of immunoglob-
ulin G heavy chain (Fc) and immediately adjacent to the
hypervariable domains of IgG (Fab)—in some cases the
sequences were conserved in more than 90 % of human IgG
sequences available for comparison in Genbank—we postu-
lated that they might induce T cells that had a regulatory or
immuno-suppressive function rather than an inflammatory
function. Proof that natural regulatory T cell (nTreg) epitopes
are present in immunoglobulin might explain why immuno-
globulins, which undergo somatic hypermutation in the pe-
riphery, do not elicit the expected immune response against
the new “foreign” hypervariable sequences. Studies summa-
rized here provide evidence that the Tregitopes indeed
provide inherent inhibitory signals. Moreover, Tregitope
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immunomodulatory signals that might counterbalance
stimulatory signals from neo-epitopes expressed in im-
munoglobulin hypervariable regions (Fig. 1) might also
be used to alter the course of autoimmune disease, allergy, and
organ transplantation.
CD4+CD25+FoxP3+ nTregs are an important component
of immune regulation in the peripheral circulation. Upon
antigen-specific activation through their T cell receptor
(TCR), nTregs suppress autoreactive T cell responses to unre-
lated antigens by both contact-dependent and -independent
mechanisms [2]. Despite extensive studies, and with few
exceptions [3, 4], the antigen specificity of nTregs is still
unknown. The peptides we identified in IgG were tentatively
named “IgG Tregitopes,” and we presented evidence that
these peptides activate T cells that constitutively express
FoxP3 and can be considered natural regulatory T cell epito-
pes. For the purpose of this discussion, we have defined
Tregitopes as peptides that 1) bind to multiple major histo-
compatability (MHC) class II molecules, 2) induce nTregs to
expand, 3) convert naïve and/or T effector cells to induced or
adaptive Tregs (iTregs or aTregs), 4) suppress effector T cell
responses to co-delivered antigen, and 5) up-regulate Treg-
associated cytokines and chemokines.
In previously published work, we demonstrated that Tre-
gitopes specifically activate CD4+CD25+FoxP3+ nTregs [1]
and modify antigen-specific immune responses, as mea-
sured in tetramer-labeled cells in vitro. In further studies,
we have demonstrated that co-incubation of antigens with
Tregitopes leads to suppression of T and B effector
responses, including suppression of antibody titers; reduced
inflammatory cytokine secretion; and reduced proliferation,
as measured by thymidine incorporation and CFSE dilution.
Tregitope homologs that are nearly identical with human
Tregitope sequences can be identified in mouse Fc and Fab;
Tregitope homologs may also be present in murine albumin
and other common murine proteins. The presence of murine
T regulatory epitopes may explain earlier observations that
Fc [5] and Fc-protein fusions stimulate tolerizing immune
responses [6] in murine models.
Induction of antigen-specific tolerance is the key to ef-
fective immunological therapy. In recent work, we have
confirmed our initial observation that concurrent incubation
or treatment with Tregitopes and antigen induces the con-
version or expansion of iTregs [7]. However, once stimulat-
ed to respond, nTregs can modulate autoimmune responses
not only by inhibiting the antigen-specific activity of auto-
reactive effectors, but also by changing the phenotype of the
T effectors to that of an iTreg. We propose that the natural
function of Tregitope-specfic T cells is to suppress anti-
idiotypic responses (Fig. 1). Thus, activated Tregitope-
specific nTregs recognize Tregitope peptides presented by
antigen presenting cells (Fig. 2, Steps 1 and 2) and directly
modulate antigen-presenting cells (Fig. 2, Step 3) and/or
nearby effector T cells, leading to the conversion of these
nearby CD4 and CD8 antigen-specific T effectors (Fig. 2,
Step 4) to antigen-specific regulatory T cells (iTregs). This
phenotypic change may be more or less transient and may
require the preservation of a regulatory milieu and repeated
treatment with Tregitopes and target antigen to allow iTregs
to be maintained over longer periods of time.
Relationship to IgG and IVIG
The role of antibodies in tolerance was described over a
century ago [8], and the success of intravenous IgG (IVIG)
therapy emphasizes the effectiveness of antibodies as im-
mune regulators. The presence of Tregitopes in IgG may
explain, in part, why IVIG therapy is efficacious in treating
autoimmune diseases or in inducing tolerance in organ
Fig. 1 Tregitopes are highly conserved Treg epitopes found in
IgG. They are postulated to reduce the immunogenicity of neo-
epitopes in the hypervariable region of IgG CDR. De Groot AS,
Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P,
et al. Activation of natural regulatory T cells by IgG Fc-derived
peptide “Tregitopes.” Blood. 2008; 112(8):3303–11. American
Society of Hematology, Copyright 2012. Reproduced with permis-
sion of American Society of Hematology (ASH)
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transplantation [9, 10]. The presence of natural T regulatory
epitopes in IgG also may explain the effectiveness of IVIG
as a therapy for factor VIII inhibitors (Bonn-Malmö proto-
col) [11, 12], for suppressing immunological rejection after
transplantation (increased Treg suppression of graft-versus-
host-disease [GVHD]) [13], and for allergic and autoim-
mune conditions [14, 15]. The identification and character-
ization of Tregitopes may be a novel and clinically
important way to harness the utility of IVIG and apply it
in a specific and quantitative manner.
IVIG’s effects have also been attributed to binding of the
IgG Fc domain to Fc-gamma receptors, blockade of the FcRn
receptor or CD95, and/or interaction of sialylated Fc with a
dendritic cell lectin receptor SIGN-R1 [16, 17]. Howev-
er, these models have never adequately accounted for
the increase of Treg cells after IVIG treatment in psoriasis,
skin transplants [18, 19], and experimental autoimmune en-
cephalomyelitis (EAE) [20]. We propose that Tregitopes may
be responsible for IVIG-induced tolerance; this hypothesis is
corroborated by published reports that polyclonal immuno-
globulin therapies induce expansion of Tregs and IL-10 se-
cretion in vivo in animals and humans [21, 22].
The effect of IVIG on inflammation is achieved at
amounts of IgG much higher than normally present in the
blood. At these doses, multimeric complexes of IVIG may
be formed, and the natural salvage pathway for IgG through
FcRn (which normally protects IgG from degradation [23])
may be overwhelmed. Excess IgG and immune complexes are
targeted for degradation in antigen-presenting cells such as
macrophages and dendritic cells. Because we know that anti-
gen associated with IgG immune complexes is processed and
presented in the context of major histocompatibility complex
(MHC) to T cells [24], we propose that degraded IgG in
immune complexes may result in concurrent presentation of
Treg epitopes that are contained within IgG.
In addition, the study of IVIG carried out by Anthony
and Ravetch [25] indicates that IVIG contains some Ig
molecules that have sialylated Fc, and that this fraction
binds to SIGN-R1, a surface lectin receptor that targets
sialylated proteins for degradation and antigen processing.
Binding of the sialylated fraction of IVIG could be one
means by which Tregitopes in IgG are internalized, pro-
cessed, and presented in the context of MHC. However,
sialylation of Fc does not appear to be an absolute require-
ment for tolerance induction by IVIG [26]. In fact, non-
glycosylated peptide Tregitopes administered in saline have
effects that recapitulate IVIG in vivo (see below). In addi-
tion, Tregitope effects are positively correlated with MHC
binding, suggesting that the ultimate “receptor” for Tregi-
topes contained in IgG is MHC.
In addition to the Tregitopes identified in Fc, we have
identified Tregitopes in the highly conserved framework
regions of IgG Fab. A number of tolerogenic Fab-derived
peptides have been described by other investigators [27–30].
Some of these peptides have been evaluated in clinical trials
[30]. These peptides overlap with Fab-region Tregitopes, de-
fined independently by our group, but are relatively MHC-
and human leukocyte antigen (HLA)-restricted, based on Epi-
Matrix analysis. Independent confirmation of tolerogenic
properties for these MHC-binding peptides by the Mozes
laboratory provides evidence that Tregitopes are active in vitro
and in vivo [30].
The five IgG-derived peptides described in Table I repre-
sent the best-characterized candidate Tregitopes that we have
identified to date. These peptides were originally selected
because of the presence of a high density of diverse MHC
binding motifs (“promiscuity score”) and have been shown to
bind promiscuously to human and murine MHC. Human and
murine homologs of Tregitopes 167 and 289 have been stud-
ied extensively at EpiVax and by our collaborators; a high-
level summary of recent results is provided in the following
section. They are immunosuppressive in human ex vivo
assays and, in their murine form, in BALB/c, C57BL/6, and
NOD mice. Human Tregitopes 009 and 029 have been shown
to suppress immune response in human ex vivo assays. The
presence of certain Fab-region Tregitopes in licensed mono-
clonal antibodies is highly correlated with lower immunoge-
nicity [31 and EpiVax unpublished data].
Fig. 2 Proposed Tregitope mechanism of action. The following step-
by-step sequence of events may lead to nTreg activation, antigen-
presenting cell (APC) modulation, and either suppression of T effectors
or induction of iTregs in the presence of Tregitopes: (Step 1) Tregi-
topes are presented by activated APC to Tregs that have Tregitope-
specific TCR. These nTregs then either indirectly through cytokine
release (Step 2), or directly suppress the activation of (Step 3) antigen-
presenting cells (macrophages, B cells, dendritic cells, or others),
resulting in downregulation of the co-stimulatory signaling molecules
CD80, CD86, and MHC class II. The cytokines released by the nTregs
either directly affect (Steps 4 and 5) the functioning of CD4 effector T
cells, CD8 T cells, and Th17 T cells; or indirectly regulate (Step 3)
these cells through APC or direct cell-to-cell contact. Adapted from [2]
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Overview of Tregitope Research to Date
We have studied the effect of Tregitopes in several murine
model systems. These include C57BL/6 and Balb/C mice
(standard antigen immunization studies, using antigens such
as ovalbumin (OVA); Scott, unpublished); NOD mice [7];
D011.10 TCR Tg mice (Su and Scott, unpublished); and
bm12/ABM mice [32]. Tregitopes reduced the incidence of
diabetes in NOD mice when administered prior to the
development of diabetes; Tregitopes also suppressed the
development of diabetes in a therapeutic model (treatment
following two consecutive blood sugar levels exceeding
250 g/dL). In each of the models described above, Tregitope
therapy effectively suppressed T cell responses in vivo. Sup-
pression was measured in terms of cytokine expression, upre-
gulation of nTreg and iTregs in vivo, and, in the case of bm12
into C57BL/6 mice, expansion of antigen-specific T cells.
Tregitopes have been administered with a variety of
antigens. For example, the Najafian-Sayegh group has
evaluated the mechanism of action in mixed lymphocyte
reaction (MLR) studies in which the targets are alloan-
tigens, as well as in vivo in models in which the target
antigen is well defined (a single T cell epitope that is
mismatched in bm12 to C57BL/6 skin transplant) and
for which TCR transgenic mice are available (ABM)
[32]. Mazer and Keegan have performed in vivo studies
of Tregitope treatment in airway disease following in-
duction of allergy in OVA-sensitized mice [33 and un-
published studies], Mingozzi and High have performed
in vitro CD8+ T cell assays using both AAV and EBV
antigens [34], and Elyaman and Khoury have adminis-
tered Tregitopes with myelin oligodendrocyte glycopro-
tein (MOG) peptides in EAE [35].
Tregitope treatment effectively suppressed immune
responses to the co-administered antigens in each of these
systems, despite the varied nature of the antigens and the
underlying bias of the immune response (Th1 in the case of
MLR, Th2 in OVA, and Th17 in EAE). In each of these studies,
concurrent treatment with a control peptide with similar MHC
binding properties (tetanus toxin epitopes, influenza epitopes,
and autologous MHC binding peptides such as GAD and
insulin peptides) did not suppress immune response to the
same degree as Tregitopes alone or Tregitopes administered
with the target antigen. The effect of Tregitopes may be long-
lasting inmice; we have observed effective immune suppression
to alloantigens at 100 days in the transplant model [32] and
reversal of diabetes for as long as 26 weeks in NOD mice [7].
Tregitopes’ mechanism of action has been the subject of
extensive study. The current model is illustrated in Fig. 2,
which also shows the immune system components that are
believed to be involved in modulation of the immune re-
sponse by Tregitopes. First, Tregitopes are recognized in the
context of MHC by circulating Tregs (Fig. 2 [Step 1]). This
leads to expansion and activation of the nTregs (Fig. 2 [Step
2]); IL-10 and TGF-beta are secreted and the phenotype of
antigen-presenting cells is either directly or indirectly al-
tered, leading to downregulation of co-stimulatory mole-
cules (CD80, CD86, MHC class II) on the antigen-
presenting cell surface and upregulation of tolerogenic factors
such as ILT3 (Cousens et al., manuscript in preparation).
Suppression of co-stimulatory molecules leads to direct
suppression of CD4 and CD8 T effector cells (Fig. 2 [Steps
3 and 4, Najafian and Mingozzi, unpublished studies]).
Indirect effects may occur due to cytokines or direct contact
between Tregs and T effectors (Fig. 2 [Steps 4 and 5]).
Mingozzi and High have preliminary evidence that the
nTregs directly contact CD8 T cells, modulating their
responses in an antigen-specific manner (Mingozzi et al.,
manuscript in preparation; not shown in Fig. 2).
Due to the complex interplay of antigen-presenting cells,
nTregs, T effector cells, and iTregs, the effects of Tregitope
treatment in vitro and in vivo appear to be pleiotropic. This
indicates that Treg responses to these peptides impact other
cells central to the induction and maintenance of inflamma-
tion, e.g. antigen-presenting cells such as dendritic cells and,
potentially, B cells. Thus, it is now somewhat less surprising
Table I Five tregitopes found in IgG
Tregitope Amino
acids
Validation studies # MHC
motifs




HTREG_IGGC-167 26 Published (De Groot et al. Blood 2008) 20 30.05 CH1
HTREG_IGGC-289 21 Published (De Groot et al. Blood 2008) 14 22.57 CH2
HTREG_IGGH-009 15 HLA-binding, Treg induction 7 14.07 VH
HTREG_IGGH-029 15 HLA-binding, Treg induction 7 14.09 VH
HTREG_IGGK-084 15 HLA-binding, Treg induction 7 16.38 VK
The five best-defined human IgG-derived Tregitopes listed above are 15 to 26 amino acids in length and have multiple HLA binding motifs and
high EpiMatrix scores. These Tregitopes are located in the IgG constant domain (CH) and variable domains (VH, VK). Several mouse IgG
homologs for these Tregitopes have been identified, although hTregitopes 167 and 289 bind to mouse MHC and, in a murine model of EAE,
suppressed symptoms of EAE as well as IVIG [1, 31]
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to find that treatment with Tregitopes can suppress humoral
immune responses to co-administered antigens, induce
adaptive T cells (aTreg or iTreg), suppress CD8+ T cell
responses in an antigen-specific manner, suppress Th17
cells, and suppress reactive airway responses and IgE in
an OVA model of allergy. Regardless of their site of action,
Tregitopes are an attractive therapeutic intervention because
they appear to modulate immune responses through natural
networks, shifting the balance of immune responses to re-
establish tolerance.
Conclusions
We have studied Tregitopes and their activities in a range of
model systems, proposed a mechanism of action of Tregi-
topes, and described their potential as modulators of toler-
ance in transplantation, gene therapy, and autoimmune
disease. Information about Tregitopes present in monoclo-
nals and Fc fusions has already had dramatic impact on the
field of protein therapeutics. Indeed, a careful review of
monoclonal antibody immunogenicity in clinical practice
has already revealed a correlation between the presence of
human Tregitopes and less immunogenic monoclonals [31],
and the concept has been integrated into preclinical immu-
nogenicity screening by a number of large biotech compa-
nies. Tregitopes also may be present in other proteins, as
illustrated by studies carried out with albumin, a common
excipient in protein therapeutics [36].
The use of Tregitopes is quite different from other emerg-
ing approaches for the induction of Tregs such as the anti-
CD3 monoclonal antibodies teplizumab and otelixizumab.
Anti-CD3 treatment has shown some efficacy in human
studies, but the mechanism of Treg induction is elusive
and the effect appears to be brief [37, 38]. Potential advan-
tages to the Tregitope approach are induction of circulating
Tregitope-specific nTregs, specificity of the tolerance to the
co-administered antigen, and highly localized immunosup-
pressive effects. Induction of antigen-specific adaptive tol-
erance using Tregitopes that are co-delivered, linked, or
fused to Tregitope peptides may be the key to treatment of
autoimmune disease for which the target antigens have been
identified; this would probably be effective for the treatment
of allergies as well. Induction of tolerance using targeted
Tregitope therapy may reduce the repeated and long-term
treatments necessary to treat autoimmune diseases and al-
lergies, if restoration of tolerance is achieved. Off-target
effects generally associated with teplizumab and otelixizu-
mab and other systemic immunosuppressive therapies
(Cytoxan, prednisone) might be avoided if existing therapies
for severe allergies and autoimmune diseases were replaced
with or augmented by Tregitopes. However, maintaining
tolerance induced by Tregitope therapy in humans may
require “booster” treatments (Tregitopes and target antigen)
and/or intermittent low-dose IL-2 to maintain iTreg popula-
tions [39].
Similarly, Tregitope therapy may also modulate pre-
existing and de novo immune responses to adeno-associated
virus (AAV) vectors, which are a major barrier to successful
gene transfer. Integration of Tregitope into the AAV capsid
has shown some promise in preliminary experiments con-
ducted by Mingozzi et al., and induction of tolerance to
AAV vectors could have wide-reaching effects for the gene
transfer field. Finally, restoring natural tolerance to self or
creating artificial tolerance to transplanted organs would alle-
viate the burden of repeated and long-term medical interven-
tions required as part of the treatment for transplants.
As the discovery of Tregitopes may explain some effects
of IVIG therapy, biomarkers of Treg activity may be impor-
tant adjuncts to clinical trials of IVIG. Already, induction of
IL-10, downregulation of CD154, and modification of sur-
face expression of Notch and Jagged have been identified as
potential markers of the Tregitope effect (Cousens, Elyaman,
unpublished). Induction of nTregs specific for Tregitope may
eventually be measurable in the clinical setting by staining
CD4 T cells with Tregitope tetramers.
The duration and specificity of the Tregitope effect will
be examined in ongoing safety studies. As the mechanism of
action of Tregitopes closely parallels that of intravenous IgG
(IVIG), a comparison with IVIG’s record of safety would
appear to be appropriate. It is interesting to note that long
term IVIG treatment has not been associated with increased
cancer rates nor has it been associated with increased infec-
tions, thus we believe that Tregitopes will be relatively safe
for long-term use. Dosing frequency is also under study;
however, the effects of Tregitopes have been measured out
to 26 weeks in the NOD model. If the antigen-specific effect
of Tregitopes is due to the induction of relatively unstable
antigen-specific Tregs, it is likely that Tregitope treatments
will need to be repeated so as to maintain their effect. This
may be an inconvenience, but it would also mean that
Tregitope effects would be reversible. Thus we anticipate
that Tregitopes will be safe and non-toxic and that their
effects will be long-lasting but not permanent, unless a
persistent form of co-expression with target antigen can be
developed.
Future studies will elucidate key questions related to the
duration of the Tregitope effect, clarify the number of
nTregs that are Tregitope-specific, enable better understand-
ing of the mechanism of Tregitope action, and uncover
additional biomarkers of Tregitope activity. In addition,
these studies will enable researchers to identify means of
delivering Tregitopes directly to sites of inflammation,
where it is presumed that they will induce nTregs to respond
and suppress or convert allo- and/or auto-immune responses
to adaptive tolerance.
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